Potent in vivo antineoplastic activity of MCR peptides MCR-4 and MCR-14 against chemotherapy-resistant human small cell lung cancer

Drugs under Experimental and Clinical Research

Volumn 29, Issue 2, 2003, Pages 69-74

  Radulescu, Razvan T ^a,c   Jaques, G ^b  

^a Molecular Concepts Research MCR   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c Molecular Concepts Research (MCR)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; LEUCYLPHENYLALANYLTYROSYLLYSYLLYSYLVALYLARGINYLGLUTAMINYLISOLEUCYLLYSYLISOL EUCYLTRYPTOPHYLPHENYLALANYLGLUTAMINYLASPARAGINYLARGINYLARGINYLMETHIONYLLYSYLTRYP TOPHYLLYSYLLYSINE; LYSYLARGINYLLYSYLARGINYLSERYLPROLYLVALYLARGINYLSERYLLEUCYLPHENYLALANYLTYROS YLLYSYLLYSYLVALYLTYROSYLARGINYLLEUCYLALANYLPROLYLLYSYLTHREONINE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; PEPTIDE FRAGMENTS; PEPTIDES; RETINOBLASTOMA PROTEIN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0043029705     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Zheng L., Lee W.-H. The retinoblastoma gene: A prototypic and multifunctional tumor suppressor. Exp. Cell Res., 264, 2, 2001.
2. Harrington E.A., Bruce J.L., Harlow E., Dyson N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc. Natl. Acad. Sci. USA, 95, 11945, 1998.
3. Brugarolas J., Moberg K., Boyd S.D., Taya Y., Jacks T., Lees J.A. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after γ-irradiation. Proc. Natl. Acad. Sci. USA, 96, 1002, 1999.
4. Cobrinik D., Dowdy S.F., Hinds P.W., Mittnacht S., Weinberg R.A. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem. Sci., 17, 312, 1992.
5. Wendtner C.M., Radulescu R.T. Prediction of homologous binding sites on RB and p107 common for viral oncoproteins and cellular ligands. J. Mol. Recognit., 5, 125, 1992.
6. Radulescu R.T, Wendtner C.M. Proposed interaction between insulin and retinoblastoma protein. J. Mol. Recognit., 5, 133, 1992.
7. Radulescu R.T., Bellitti M.R., Ruvo M., Cassani G., Fassina G. Binding of the LXCXE insulin motif to a hexapeptide derived from retinoblastoma protein. Biochem. Biophys. Res. Commun., 206, 97, 1995.
8. Radulescu R.T., Jaques, G. Selective inhibition of human lung cancer cell growth by peptides derived from retinoblastoma protein. Biochem. Biophys. Res. Commun., 267, 71, 2000.
9. Radulescu R.T., Cybon C., Manuilova T., Jaques G. MCR peptides suppress human lung cancer growth in vitro and in vivo. Clin. Cancer Res., 6 (Suppl.), S4564, 2000.
10. Harbour J.W., Lai S.-L., Whang-Peng J., Gazdar A.F., Minna J.D., Kaye F.J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science, 241, 353, 1988.
11. Dou Q.P., Lui V.W. Failure to dephosphorylate retinoblastoma protein in drug-resistant cells. Cancer Res., 55, 5222, 1995.
12. Soni R., O'Reilly T., Furet P., et al. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst., 93, 436, 2001.
13. Hruby V.J. Peptide science - whither thou goest? J. Peptide Res., 56, 1, 2000.